Since the approval of Orthoclone OKT3 in 1986, more than 100 monoclonal antibodies (mAbs) have been approved by the Food and Drug Administration (FDA) to treat a variety of diseases ranging from autoimmune disorders, infectious diseases, and cancer [1-2]. In the context of the current COVID-19 pandemic, its crucial that these biologics are developed rapidly and efficiently. Among various antibody discovery approaches, including hybridoma technology, single B cell screening is a powerful and efficient strategy for generating antigen-specific mAbs based on the direct amplification of the VH and VL regions encoding genes from single B cells [3-4]. Notably, single B cell screening has various advantages that include maintaining the naïve VH/VL pairing, requiring relatively few cells, and the ability to discover antibodies against challenging targets.
Swedish Bioinvent issues shares worth SEK299m (USD28m)
Latest NewsBioInvent has successfully carried out a directed share issue of approximately SEK 300 million (approximately USD 28.3 million). A number of international and Swedish investors participated, including new investors such as AXA Investment Managers and a US institutional investor and the existing shareholders Forbion, HBM Healthcare Investments, Redmile Group, Invus, the Fourth National Swedish Pension Fund and Swedbank Robur Fonder, with demand for the new shares exceeding the size of the planned volume.
Accelerom Automated Sample Preparation Platform
ProductsBreak free from the long reaction times, high costs, and method complexity of manual proteomic sample preparation with the Thermo Scientific AccelerOme automated sample preparation platform. With factory-supplied reagents and kits, and step-by-step onscreen instructions, high reproducibility and confident results are delivered for both label-free and tandem mass tag (TMT) multiplexing strategies with minimal effort. The AccelerOme platform is optimized to fit into the Thermo Scientific Orbitrap mass spectrometer ecosystem, streamlining the entire workflow from sample preparation to data processing.
Immunocore has a sip with USD140m private placement
Latest NewsImmunocore sells around 3.7m shares in a private placement with a 20% discount and gets USD140m to advance its pipline.
Worldview national ranking of health biotech sectors
BackgroundA current Nature study specifies the most competitive health biotech sectors worldwide and puts Switzerland at the top, Sweden second and the USA third. Does the new math convince?
GSK splits off consumer health as Haleon – first stock listing today
Latest NewsGlaxoSmithKline (GSK), one of the UKs large pharma player, has voted to spin-off its consumer healthcare business into a new company called Haleon. Shareholders gave the go-ahead for GSK to demerge on 6, July, first trading day is today, 18th of July.
Polpharma Biologics Announces EMA Acceptance for Proposed Biosimilar Natalizumab (Tysabri)
Latest NewsEuropean Medicines Agency (EMA) has accepted the application for biosimilar natalizumab, a proposed biosimilar to Tysabri® (Biogen) in the indication of Multiple Sclerosis (MS).
Nanobodies: An Important Tool for the Next Generation of Tumor Diagnostics and Therapeutics
Sponsored PublicationsNanobodies are emerging as important tools for tumor diagnosis and treatment due to their small size, simple humanization, low immunogenicity, superior affinity and stability, high penetration, and adequate levels of solubility, and are expected to revolutionize the antibody-based drug therapy. In 2018, the worlds first nanobody was approved for marketing in the European Union to treat adult patients with acquired thrombotic thrombocytopenic purpura. At present, more than 20 nanobodies are being tested in clinical research worldwide, mostly in clinical phase I or II.
Discovering Antigen-specific Monoclonal Antibodies using Single B Cell Screening
Sponsored PublicationsSince the approval of Orthoclone OKT3 in 1986, more than 100 monoclonal antibodies (mAbs) have been approved by the Food and Drug Administration (FDA) to treat a variety of diseases ranging from autoimmune disorders, infectious diseases, and cancer [1-2]. In the context of the current COVID-19 pandemic, its crucial that these biologics are developed rapidly and efficiently. Among various antibody discovery approaches, including hybridoma technology, single B cell screening is a powerful and efficient strategy for generating antigen-specific mAbs based on the direct amplification of the VH and VL regions encoding genes from single B cells [3-4]. Notably, single B cell screening has various advantages that include maintaining the naïve VH/VL pairing, requiring relatively few cells, and the ability to discover antibodies against challenging targets.
Agomab extenses Series B with USD40m Bringing Total Amount to USD114m
Latest NewsAgomab Therapeutics NV from Ghent, Belgium, today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount raised to $114 million. Pfizer led the extension with an investment through its Pfizer Breakthrough Growth Initiative.
ACHEMA 2022, 22 – 26 August 2022 in Frankfurt, Germany
Sponsored PublicationsACHEMA is the world forum and leading trade show for the chemical, pharmaceutical and food industries. It’s where new developments are unveiled and trends are discussed.